<i>In vitro</i> susceptibility testing of <i>Malassezia pachydermatis</i> to gentamicin

Silva, Freddy A.; Ferrer, O.; Déniz, S.; Rosario, Inmaculada; Conde-Felipe, Magnolia; Díaz, Esther Licia; Acosta-Hernández, Begoña

doi:10.1111/vde.12427

Cited by 4 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Etest ® method was used for determination of the MIC50 and MIC90 to netilmicin, gentamicin and tobramycin. The MIC50 and MIC90 obtained by the Etest ® method for gentamicin were in accordance with that obtained by Silva et al using microdilution method according the CLSI M27‐A3 method, in which the MIC50 and MIC90 were found to be 8.12 and 32.5 μg/mL respectively. The Etest ® appears to be a reliable method for estimating MICs in M. pachydermatis .…”

Section: Discussionsupporting

confidence: 76%

“…The CLSI has standardised the M44‐A2 method as the disk diffusion method for yeast; this method has been tested with some antifungal agents but this has not been tested with antimicrobial agents, since antibacterial active against yeast have never been reported except for gentamicin by Silva et al. Our results obtained for the framycetin show that it could be a good candidate for inhibiting M. pachydermatis growth, evidenced by the zone diameters of the 70 strains, which ranged from 16 to 28 mm.…”

Section: Discussionmentioning

confidence: 80%

“…When comparing our results by Etest ® for gentamicin with those obtained by Silva et al with the microdilution method, we observe that the results of sensitive and intermediate strains are similar. We found a small difference in resistant strains, 11.42% for Etest ® vs 5.71% obtained by microdilution method …”

Section: Discussionmentioning

confidence: 80%

“…Malassezia pachydermatis isolates from small animals has showed susceptibility to gentamicin and MIC50 and MIC90 were 8.12 μg/mL and 32.5 μg/mL by microdilution method . The aim of this study was to evaluate the in vitro susceptibility of M. pachydermatis strains (derived from small animals) to aminoglycosides, including gentamicin, tobramycin, netilmicin and framycetin.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Susceptibility of Malassezia pachydermatis to aminoglycosides

Silva

Conde-Felipe

Rosario

et al. 2017

Mycoses

Self Cite

View full text Add to dashboard Cite

Previous studies have evaluated the action of gentamicin against Malassezia pachydermatis. The aim of this study was to evaluate in vitro susceptibility of M. pachydermatis to the aminoglycosides- gentamicin, tobramycin, netilmicin and framycetin. The minimum inhibitory concentration (MIC) of gentamicin was determined following methods M27-A3 microdilution and Etest . The Etest was used to determine the minimum inhibitory concentration (MIC) of the tobramycin and netilmicin. The Kirby-Bauer test was used to determine the antibiotic susceptibility to the framycetin. The MIC50 and MIC90 were 8.12 μg/mL and 32.5 μg/mL by microdilution method for gentamicin. The MIC50, determined by the Etest , was 8 μg/mL for gentamicin and netilmicin and 64 μg/mL for tobramycin. The MIC90 was 16 and 32 μg/mL for gentamicin and netilmicin respectively. The MIC90 was outside of the detectable limits for tobramycin. To framycetin, 28 strains (40%) of the 70 M. pachydermatis isolates tested showed a diameter of 22 mm, 22 strains (31.42%) showed a diameter of 20 mm, 16 strains showed a diameter of ≤ 18 mm, and only 5.71% of the isolates showed a diameter of ≥ 22 mm. This study provides evidence of high in vitro activity of the aminoglycosides-gentamicin, tobramycin, netilmicin and framycetin against M. pachydermatis. For gentamicin Etest showed similar values of MIC50 y MIC90 that the obtained by microdilution method. We considered Etest method could be a good method for these calculations with aminoglycosides.

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 80%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Susceptibility of Malassezia pachydermatis to aminoglycosides

Silva

Conde-Felipe

Rosario

et al. 2017

Mycoses

Self Cite

View full text Add to dashboard Cite

show abstract

“…[12,13,22] Identificar específicamente el agente causal de las diferentes infecciones micóticas nos permite conocer mejor su epidemiología, distribución geográfica y patogenia, así como también la elección de los antifúngicos para un tratamiento adecuado. [1,2,9,10,11,13,14,15,16,17]. …”

Section: Discussionunclassified

Dermatitis Facial por Malassezia pachydermatis.

velez

2018

Bol. Micol.

View full text Add to dashboard Cite

REsumEnSe presenta un caso de dermatitis facial por Malassezia pachydermatis en un paciente de 34 años de edad, diagnosticado mediante clí-nica y estudio micológico. M. pachydermatis es una levadura que forma parte de la microbiota de mamíferos domésticos y animales salvajes, donde frecuentemente puede provocar dermatitis y otitis externa. En humanos, son escasas las infecciones por este agente, describiéndose desde infecciones superficiales hasta fungemias. En Chile se la ha encontrado como agente causal de pitiriasis versicolor y dermatitis seborreica principalmente en pacientes inmuno-comprometidos. AbstRActWe present a clinical case of facial dermatitis due to Malassezia pachydermatis in a patient of 34 years old, diagnosed by clinical and micology study. M. pachydermatis is a zoofilic yeast that is part of the microbiota of domestic mammals and wild animals, frequently causing dermatitis and external otitis. In humans, infections by this agent are very scarce, describing from superficial infections to fungemias. In Chile it has been found as causal agent of pitiriasis versicolor and seborrheic dermatitis mainly in inmunocompromised patients. IntRoDuccIónEl estudio de las micosis de la piel comienza en el siglo XIX con Schönlein (1839) quien describe por primera vez el origen micótico de ciertas lesiones en la piel [19], lo que se confirmó con Eichstedt (1846), quien observó levaduras e hifas cortas en la piel de pacientes con pitiriasis versicolor [1,2,19]. Robin denominó a este agente Microsporum furfur (1853) y posteriormente Malassez (1874) informó la presencia de células brotantes en las células del estrato córneo. Pero no fue sino hasta 1889 cuando Baillon crea el géne-ro Malassezia en honor a Malassez y describió a Malassezia furfur como especie tipo [1,2,3]. Por otra parte Sabouraud creó el género Pityrosporum para referirse a la forma levaduriforme y mantu- Bol.Micol. 2018; 33(1):21-25 mIcoLoGIA mEDIcA micologia.uv.cl

show abstract

Biology, diagnosis and treatment ofMalasseziadermatitis in dogs and cats Clinical Consensus Guidelines of the World Association for Veterinary Dermatology

Bond

Morris

Guillot

et al. 2020

Veterinary Dermatology

118

View full text Add to dashboard Cite

Background -The genus Malassezia is comprised of a group of lipophilic yeasts that have evolved as skin commensals and opportunistic cutaneous pathogens of a variety of mammals and birds.Objectives -The objective of this document is to provide the veterinary community and other interested parties with current information on the ecology, pathophysiology, diagnosis, treatment and prevention of skin diseases associated with Malassezia yeasts in dogs and cats.Methods and material -The authors served as a Guideline Panel (GP) and reviewed the literature available prior to October 2018. The GP prepared a detailed literature review and made recommendations on selected topics. The World Association of Veterinary Dermatology (WAVD) Clinical Consensus Guideline committee provided guidance and oversight for this process. The document was presented at two international meetings of veterinary dermatology societies and one international mycology workshop; it was made available for comment on the WAVD website for a period of six months. Comments were shared with the GP electronically and responses incorporated into the final document.Conclusions and clinical importance -There has been a remarkable expansion of knowledge on Malassezia yeasts and their role in animal disease, particularly since the early 1990's. Malassezia dermatitis in dogs and cats has evolved from a disease of obscurity and controversy on its existence, to now being a routine diagnosis in general veterinary practice. Clinical signs are well recognised and diagnostic approaches are well developed. A range of topical and systemic therapies is known to be effective, especially when predisposing factors are identified and corrected.

show abstract

In vitro susceptibility testing of Malassezia pachydermatis to gentamicin

Abstract: Prospective MICs for M. pachydermatis have been established for gentamicin.

Cited by 4 publications

References 22 publications

Susceptibility of Malassezia pachydermatis to aminoglycosides

Susceptibility of Malassezia pachydermatis to aminoglycosides

Dermatitis Facial por Malassezia pachydermatis.

Biology, diagnosis and treatment ofMalasseziadermatitis in dogs and cats Clinical Consensus Guidelines of the World Association for Veterinary Dermatology

Contact Info

Product

Resources

About